Pharmaceutical companies continue to operate in an environment influenced by regulatory developments, competitive pressures and evolving demand across therapeutic markets. Against this backdrop, Elite Pharmaceuticals, Inc. (ELTP Quick QuoteELTP - Free Report) and Aytu BioPharma, Inc. (AYTU Quick QuoteAYTU - Free Report) are two pharmaceutical companies with exposure to central nervous system (CNS) treatments, including the attention deficit hyperactivity disorder (ADHD) market. However, the companies follow different approaches, with ELTP primarily focused on generic pharmaceuticals and AYTU emphasizing branded prescription medicines.

While both companies participate in overlapping therapeutic areas, their differing product portfolios and commercial strategies create distinct growth opportunities and risk profiles. These differences raise the question: which company is better positioned to deliver long-term shareholder value? Let’s take a closer look.

Stock Performance & Valuation: ELTP vs. AYTU

ELTP (down 34.9%) has underperformed AYTU (down 5.9%) over the past three months. In the past year, Elite Pharmaceuticals stock has plunged 62.1% compared with Aytu’s dip of 13.5%.

Image Source: Zacks Investment Research

Meanwhile, ELTP is trading at a trailing 12-month enterprise value-to-sales (EV/S) ratio of 1.6X, below its median of 2.6X over the past five years. AYTU’s trailing 12-month EV/S multiple sits at 0.1X, in line with its last five-year median. ELTP and AYTU both appear to be cheap when compared with the Zacks Medical sector’s average of 2.8X.

Image Source: Zacks Investment Research

Factors Driving Elite Pharmaceuticals Stock

Elite Pharmaceuticals’ existing generic portfolio continues to gain traction, particularly across lisdexamfetamine, mixed amphetamine IR (Immediate Release) and ER (Extended Release), and naltrexone. Management indicated that market share has been increasing across these major products while pricing has stabilized following the initial adjustment in the generic Vyvanse market. That combination is important because it points to a more durable commercial base, with ELTP benefiting from higher volumes and an established position as a dependable supplier in categories where scale and consistency matter.

The pipeline remains a key avenue for broadening future growth. Elite Pharmaceuticals has recently added methadone and generic Requip XL to its commercial portfolio while continuing to advance additional opportunities in areas such as anticoagulants, anticonvulsants and generic OxyContin. Management has repeatedly emphasized that prior product launches were central to ELTP’s historical growth, and the current pipeline could help reduce reliance on its core ADHD-focused products over time.

Elite Pharmaceuticals’ financial position and manufacturing readiness also support its growth outlook. The company continues to generate positive operating cash flow and has built a stronger liquidity position. Management is also evaluating facility improvements and added manufacturing capacity so the business can support higher production volumes as its commercial portfolio expands. That gives ELTP greater flexibility to scale operations while relying less on outside financing.

Factors Aiding Aytu Stock

Aytu’s EXXUA launch is emerging as the company’s clearest growth catalyst. Prescription activity has continued to build as more physicians gain experience with the drug, while repeat prescribing and refill activity suggest that adoption is extending beyond initial trial use. Management has also pointed to encouraging patient persistence and broadening utilization across territories. Combined with EXXUA’s differentiated mechanism and tolerability profile in major depressive disorder, this gives AYTU a potentially meaningful branded growth engine.

The legacy ADHD portfolio continues to provide a durable commercial base despite generic competition. Adzenys and Cotempla have maintained meaningful prescription demand even after promotional support was reduced, and AYTU’s authorized-generic strategy helps preserve participation as competitive conditions evolve. This is important because the ADHD business remains a source of profit and cash generation, giving Aytu a more stable foundation while it scales EXXUA.

Aytu’s existing commercial platform provides meaningful operating leverage. The company’s RxConnect patient-access network, focused sales organization and analytics capabilities are already in place to support prescription growth and improve access. That infrastructure can support EXXUA and other portfolio products without requiring a full commercial rebuild, which may improve the efficiency of future growth and help management remain disciplined on spending.

Choose ELTP Over AYTU Now

Elite Pharmaceuticals and Aytu both offer exposure to CNS-focused pharmaceutical markets, but their investment cases are built on different foundations. ELTP is supported by an established generic portfolio that continues to gain market share, a growing pipeline of additional products and a strengthening financial position. Its existing commercial base and internal manufacturing capabilities provide a relatively balanced platform for future growth.

AYTU’s investment case is more centered on the commercial ramp of EXXUA, which has emerged as its primary growth catalyst. Early prescription and physician-adoption trends are encouraging, while the legacy ADHD portfolio continues to provide a useful source of cash generation. Aytu also benefits from an established commercial infrastructure that could create operating leverage as EXXUA scales. However, its outlook remains more dependent on successful execution around a relatively new product.

From a valuation perspective, both stocks appear inexpensive relative to the broader sector. Aytu is valued more conservatively, which suggests investors are assigning limited value to its future growth potential and remain cautious about execution risk. That could create meaningful upside if EXXUA adoption accelerates, but it also reflects the greater uncertainty surrounding the company’s path to sustained profitability. Elite Pharmaceuticals’ valuation, while higher than Aytu’s, remains below its own historical norm, suggesting the market may not yet be fully pricing in its improving product breadth and operating momentum.

Considering fundamentals alongside valuation, ELTP appears to be the better buy at present. AYTU offers a potentially higher-reward turnaround story, but Elite Pharmaceuticals’ broader commercial base, expanding pipeline, financial flexibility and comparatively lower execution risk provide a more balanced risk-reward profile for investors.